Protagonist Therapeutics

Valuation Analysis

About the Company

Protagonist Therapeutics en bref

Protagonist Therapeutics (PTGX) is currently trading at 98,49 € with a market capitalization of 6,3 Md €. The 52-week range spans from 43,09 € to 99,90 €; the current price is 1.4% below the yearly high. Year-over-year revenue growth stands at +99.0%.

💰 Dividende

Protagonist Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

13 analystes évaluent Protagonist Therapeutics (PTGX) au consensus : Achat Fort. L'objectif de cours moyen est de 103,58 €, soit un potentiel de +5.17% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 87,27 € à 119,56 €.

Protagonist Therapeutics : la thèse d'investissement en détail

Protagonist Therapeutics (PTGX) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 99% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 100%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. With a beta near 1.83, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves. Short interest sits at 13.4% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

• The share is trading at 97.5% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to above-average price swings, elevated short interest (13.4%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Protagonist Therapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.